The new film by director Lee Chang-dong receives critical acclaim from foreign media outlets, with *The Hollywood Reporter* speculating on a potential Best Actress nomination. Her performance in a Korean-language film draws attention on the global stage... a local media projection, not an official Academy nomination.
The performance of actress Jeon Do-yeon has caught the attention of the American film industry. As local media outlets continue to praise Lee Chang-dong's Netflix film *Potential Love*, there is speculation that she could become the first Korean actor to be nominated for the Academy Award for Best Actress. Attention to Korean cinema is now extending beyond the director and the work to the actor's achievements.
According to domestic media reports on the 26th, *The Hollywood Reporter*, a U.S. entertainment media outlet, shed light on Jeon Do-yeon's acting career on the 25th (local time), discussing the possibility of her being nominated for the Academy Award for Best Actress through *Potential Love*. However, this is a local media projection, and there has been no official Academy announcement or nomination.
In this film, Jeon Do-yeon plays the role of Mi-ok, the wife of a laid-off worker. *The Hollywood Reporter* takes note of Jeon's ability to portray a character whose emotions cannot be simply defined, highlighting her expressive skills. Through a performance that showcases a mix of lightness, curiosity, and pain, she brings a complex vitality to the character of Mi-ok.
The Significance of Jeon Do-yeon's Hollywood Debut
The interest in this particular project is significant as it stems from a Korean film directed by Chang-dong Lee, rather than a typical Hollywood production. The Hollywood Reporter, while noting that Jeon Do-yeon is not an actor who has been particularly active in overseas works, gave considerable attention to her acting career, which includes notable films such as "Connect," "You Are My Destiny," "Secret Sunshine," and "The Housemaid." The focus was on her longstanding and accumulated acting prowess, rather than her recognition in new markets.
Positive Reception for the Film
The film, "Possible Love," has received favorable reviews. The LA Times praised the acting, screenplay, and direction, naming it as one of the best films of the year. The publication particularly highlighted Chang-dong Lee's perspective on the characters struggling with everyday life and Jeon Do-yeon's portrayal of a wife and a worker.
The recognition of Jeon Do-yeon's talent and the positive reception of the film indicate a shift in focus towards the quality of acting and storytelling, rather than solely relying on market-driven decisions.
'Possible Love' Generates Oscar Buzz: Critical Analysis of Late-Session Selling Pressure
As of the 26th, the Tomato Index, a critic metric on the renowned American film review site Rotten Tomatoes, has reached an impressive 100%. The site's Oscar forecast also highlights the potential for 'Possible Love' to secure a Best Picture nomination and for Jeon Do-yeon to be considered for the Best Actress category. However, it is essential to distinguish between critical acclaim and award predictions, as they do not always align with the actual nominations and awards.
Director Lee Chang-dong acknowledges the challenge of non-English speaking actors and films securing Oscar nominations. Despite this, he expresses hope that the Academy's recognition could serve as a platform to showcase the achievements of talented individuals on a global scale. The film's language and the actors' international presence are key factors that could potentially transcend the boundaries of traditional award evaluations.
The current achievements surrounding 'Possible Love' are not solely focused on awards but rather on the concrete evaluations from major U.S. media outlets and their nomination forecasts. The attention centered around Jeon Do-yeon's performance raises the question of whether this interest will translate into an actual Academy Award nomination, and if Korean cinema will once again create a significant milestone.



![[ESMO 2026 Analysis] HLB's Rivoceranib Delivers 11.8-Month PFS in Rare Cancer; Prepares for U.S. Launch of Lifiting](https://media.markettimes.co.kr/54-400x300.webp)